| Ytd | -2.72% | |
| 1y | 84.06% |
| Open | 7.92 | Prev Close | 7.87 | Low | 7.12 | High | 8.02 | Mkt Cap | 178.24M |
| Vol | 238.73K | Avg Vol | 487.50K | EPS | -11.61 | P/E | -0.68 | Forward P/E | -0.87 |
| Beta | 0.80 | Short Ratio | 19.48 | Inst. Own | 48.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 9.12 | 200-d Avg | 7.61 | 1yr Est | 4.50 |
Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxol
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-B
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Ac
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie
NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conf
NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). Whi
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics NASDAQ: KPTI said it entered 2026 with several near-term clinical and regula
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Co
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the
– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mi
NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with
https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commerc
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report)'s stock price passed above its fifty d
Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have received a consensus re
Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with
Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1
Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:K
HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) wit
Karyopharm Therapeutics (NASDAQ:KPTI) sees FY2026 sales of $130.000 million-$150.000 million vs $146
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed th
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDA
Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 mi